Building confidence in innovative vaccine technologies: how flexible, science-based USP standards help translate vaccine innovation into quality, consistency, and public trust

“Future standards need to reflect real‑world science, manufacturing experience, analytical challenges, and regulatory expectations.”

Vaccine science is evolving at an unprecedented pace. New manufacturing and analytical technologies, emerging platforms such as mRNA and viral vectors, and personalized immunotherapies are transforming how vaccines are designed, evaluated, and delivered. From a quality and scientific perspective, what does this evolution mean for vaccine development?

In this article, members of USP and the Biologics 3 Expert Committee (BIO3) respond to questions from Vaccine Insights editorial advisory board member Cristiana Campa, who also serves on BIO3, about the committee’s work to support vaccine innovation.

Fouad Atouf
Chief Science Officer, USP

Mark van Ooij
Chair, USP Biologics 3 Expert Committee

Bruce Carpick
Member, USP Biologics 3 Expert Committee

Neeraj Kaushal
Member, USP Biologics 3 Expert Committee

Jan Falcke
Member, USP Biologics 3 Expert Committee

Sarita Kattel
Principal Scientist, USP

Cristiana Campa
Interviewer; Vaccine Insights Editorial Advisory Board and Member, USP BIO3

Please enter your email to access content Read now